Alembic Pharmaceuticals Limited2021. 7. 26. · Launched first NDA with a partner Commenced filing in EU, Australia and Brazil 2015 Launched Aripiprazole on day-1. Established US front-end:

Alembic Pharmaceuticals Limited

Investor presentation – June 2021

BSE & NSE: APLLTD

1907 Established by Amin family

2006 FDA approves API facility

2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands

2008 FDA approves Formulation facility

2010 Pharmaceuticals business demerged from Alembic – APL listed

2012 Formed a JV, Rhizen, for NCE research

2013Launched first NDA with a partnerCommenced filing in EU, Australia and Brazil

2015Launched Aripiprazole on day-1.Established US front-end: transition to direct marketing

2016 Formed a JV, Aleor, for dermatology portfolio

2017 Acquired Orit Laboratories LLC, USA

2018FDA approves Aleor’s dermatology facility

Highest ever investment commitment across four new manufacturing facilities

2019 Formed a JV, to enter China, FDA approves Oncology oral solid facility

2021Rhizen’s out-licenced novel molecule “Umbralisib (UKONIQ)” is launched by TG Therapeutics, USA for MZL and FL

Milestones

Financial Highlights

Particulars Q1 FY22 Q1 FY21 Growth FY21

Net Sales 13.26 13.41 -1% 53.93

EBIDTA Pre R&D 4.06 5.49 -26% 22.52

Margin % 31% 41% 42%

R&D 1.67 1.43 17% 6.70

R&D % 13% 11% 12%

EBIDTA Post R&D 2.54 4.16 -39% 16.31

Margin % 19% 31% 30%

Net Profit 1.65 3.01 -45% 11.78

Capex 1.24 1.42 6.87

Debt-Equity (Net) 0.04 0.33 0.04

INR Bn

Formulations

Generics

US

3.69

-22%

-38%

Ex-US

1.97

13%

-15%

Branded

India

4.81

57%

34%

API

2.79

6%

30%

Total

13.26

-1%

4%

Business snapshot – Q1FY22

Revenue Q1FY22 (INR Bn)

Growth Q1FY22

over Q1FY21

Q1FY22 Revenue

Contribution

28%

15%Speciality 18%

Acute14%

Vet4%

21%Generics

43%

Branded36%

API21%

Growth Q1FY22

over Q4FY21

9.19 9.20

12.88

19.76 21.63

FY17 FY18 FY19 FY20 FY21

Revenue – Last 5 YearsINR Bn

US Generic

5.96

3.69

Q1FY21 Q1FY22

Revenue – Q1 FY22 INR Bn

➢ Well-established US front end having strong customer base

➢ Expanded our capabilities to deliver a diverse portfolio to the US

market

➢ 88 products launched through the US front end (2 launched in

Q1FY22), 6 products are on partner label

➢ 4 products planned to be launch in Q2FY22

Oral Solids114

Ophthalmic14

Derma17

Injectable1

Approved ANDAs

Total – 146*

Q1 FY22 : - 3 ANDA Filings, 5 Final ApprovalsCumulative : - 212 ANDA Filings, 146 Approvals* and 94 Products Launched so far

* Includes 18 Tentative Approval

CAGR - 24%

3.20 2.86

4.94 4.97

7.79


Revenue – Last 5 Years INR Bn

Ex-US Generics

1.751.97

Q1FY21 Q1FY22

Revenue : Q1 FY22 INR Bn

➢ Ex-US driven by partnership

➢ Presence in following markets

- Europe, Canada, Australia, Brazil and South Africa

➢ The business will focus on new launches across key markets

➢ Plant successfully audited by key regulatory authorities across the globe

CAGR - 25%

6.40 6.51

7.71

7.08

9.55



API

2.642.79

Q1FY21 Q1FY22

Revenue : Q1 FY22 INR Bn

➢ Sales across geographies as preferred supplier

➢ Investing in plants to create additional capacities

➢ FDA Compliant plants

➢ State of the art R&D center and Process development lab

➢ 118 DMF filings on cumulative basis

CAGR - 11%

Formulation : Vadodara, Hyderabad and USA

API : Vadodara and Hyderabad

Bio Centre : Vadodara

1200+ R&D employees with diverse skill sets

4.3 4.1 5.0

6.5 6.7

13.7%13.1% 12.7%

14.0%

12.4%

-

2.0

4.0

6.0

8.0

10.0


R&D Spend

R&D % ofsales

R&D

INR BnSignificant investments in building capabilities

20

37

29

25

29

5

18 19

30

20


Filing

Approval

ANDA – Accelerated filings & approvals

* 11 Filings &7 Approvalswere contributed by acquisition of Orit,US in FY18

R&D Capabilities

Dosage Form FY15 FY22

Oral Solids a a

Injectable r a

Oncology r a

Dermatology r a

Opthalmology r aBiologics r r

NCEs a a

Diversified Portfolio

State of the art facilities and infrastructure

* Last USFDA Inspection# Filing

Location Dosage FormAudit/Filingstatus

International Generics

F1 – Panelav General Oral Solids Mar’20*

F2 – PanelavOncology Oral Solids Jun’19*

Oncology Injectables Feb’21#

F3 – KarkhadiGeneral InjectablesOphthalmic Feb’21*

F4 – Jarod General Oral Solids Jun’20#

Aleor (JV) - Karkhadi Various derma forms Jan’20*

API

API I & II – Panelav Dec’18*

API III – Karkhadi Jan’20*

F2 - Panelav F3 - Karkhadi

F4 - Jarod Aleor (JV) - Karkhadi

12.5 12.7 13.8 14.3

15.0



Branded Business

1.83 2.36

0.87

1.92 0.36

0.53

3.42

4.80

Q1FY21 Q1FY22

Revenue – Q1 FY22

Vet

Acute

Speciality

INR Bn

Key achievements

➢ 3 Brands in top 300

➢ Market share is 1.4% of Indian Pharma space

Growth drivers

➢ Emphasis on Specialty segment

➢ 94% new launches in specialty

Marketing organization

➢ 5000 + Marketing team

➢ 17 Marketing divisions

➢ 19% Product portfolio in NLEM

➢ Caters to around 1,75,000 Doctors in India

Manufacturing facility

➢ Sikkim

CAGR - 5%

Therapy-wise Performance Q1 FY22

Q1 FY22 Q1 FY21

Therapy (%)Therapy Growth% (ORG)

Market Share %(ORG)

Alembic Growth %

(ORG)

Alembic Growth %

(PRIM)

Therapy Growth% (ORG)

Market Share

% (ORG)

Alembic Growth %

(ORG)

Alembic Growth %

(PRIM)

Cardiology 19 1.7 8 12 12 1.9 12 16

Gastrology 34 1.3 40 36 -8 1.3 -4 8

Gynecology 25 2.7 38 40 -10 2.5 -16 -30

Anti Diabetic 9 1.1 22 24 11 1.0 10 9

Orthopaedic 25 0.7 27 30 -10 0.6 -14 -31

Nephro / Uro 16 1.9 8 15 -5 2.0 7 15

Ophthalmology 30 1.5 68 68 -19 1.1 -37 -48

Dermatological 24 0.1 75 108 -4 0.1 -51 -63

SPECIALTY 23 1.4 26 29 -2 1.3 -3 -6

Anti Infective 92 3.2 131 130 -25 2.6 3 4

Cold & Cough 100 3.6 86 90 -5 3.8 -19 -19

ACUTE 94 3.3 119 121 -21 2.9 -4 -2

OVERALL 39 1.4 44 57 -5 1.4 -6 -6

4.91

6.04 6.266.97 6.87


CapexINR Bn

2725*

30*32*

41*


ROCE %

Financials : Generating consistent returns

20 21 22

26

30


EBIDTA margin %

* Capital excludes New Projects

31.34 31.31

39.35

46.06

53.93


RevenueINR Bn

6.15 6.42

8.75

12.13

16.31


EBIDTAINR Bn

4.03 4.13

5.84

8.29

11.78


Net ProfitINR Bn

CAGR - 15% CAGR - 28% CAGR - 31%

Thank you

Safe Harbour Agreement:

Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

Risks and uncertainties include general industry and market conditions and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited, to technological advances and patents attained by competitors, challenges inherent in new product development including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trend towards managed care and healthcare cost containment and governmental laws and regulations affecting domestic and foreign operations.

Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited, to inability to build production capacity to meet demand, unavailability of raw materials and failure to gain market acceptance.

Documents

Alembic Pharmaceuticals Limited2021. 7. 26. · Launched first NDA with a partner Commenced filing in EU, Australia and Brazil 2015 Launched Aripiprazole on day-1. Established US front-end: